FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas

British Journal of Cancer

Volumn 79, Issue 7-8, 1999, Pages 1262-1269

  Mann, B ^a   Gratchev, A ^a   Bohm C ^a   Hanski, M L ^a   Foss, H D ^a   Demel, G ^a   Trojanek, B ^b   Schmidt Wolf, I ^b   Stein, H ^a   Riecken, E O ^a   Buhr, H J ^a   Hanski, C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

Colorectal carcinoma; FasL; Immune escape; Metastases; Progression; TILs

Indexed keywords

FAS LIGAND; INTERLEUKIN 2 RECEPTOR; MESSENGER RNA;

ARTICLE; CARCINOMA CELL; CLINICAL ARTICLE; COLON MUCOSA; COLORECTAL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

COLORECTAL NEOPLASMS; FAS LIGAND PROTEIN; HUMANS; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; LIVER; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0032982834     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690202     Document Type: Article

References (33)

1. Ambe K, Mori M and Enjoji M (1989) S-100 protein positive dendritic cells in colorectal adenocarcinomas. Cancer 63: 496-503
2. Arai H, Gordon D, Nabel EG and Nabel GJ (1997) Gene transfer of Fas ligand induces tumour regression in vivo. Proc Natl Acad Sci USA 94: 13862-13867
3. Barth RJ, Camp BJ, Martuscello TA, Dain BJ and Memoli VA (1996) The cytokine microenvironment of human colon carcinoma. Cancer 78: 1168-1178
4. Bellgrau D, Gold D, Selawry H, Moore I, Franzusoff A and Duke RC (1995) A role of CD95 ligand in preventing graft rejection. Nature 377: 630-632
5. Branner TH, Mogli RJ, LaFace D, Yoo NJ, Mahboubi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF and Green DR (1995) Cell autonomous Fas/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373: 441-444
6. De Maria R, Boirivant M, Cifone MG, Roncaioli P, Hahne M, Tschopp J, Pallone F, Santoni A and Testi R (1996) Functional expression of Fas and Fas Ligand on human gut lamina propria T lymphocytes. J Clin Invest 97: 316-322
7. Dhein J, Walczak H, Bäumler C, Debatin KM and Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373: 438-441
8. Ehl S, Hoffmann-Rohrer U, Nagata S, Hengartner H and Zinkernagel R (1996) Different susceptibility of cytotoxic T-cells to CD95 ligand-mediated cell death after activation in vitro vs in vivo. J Immunol 156: 2357-2360
9. Foss HD, Demel G, Anagnostopoulos I, Aranjo I, Hummel M and Stein H (1997) Uniform expression of cytotoxic molecules in anaplastic large cell lymphoma of Null/T-cell phenotype and in cell lines derived from anaplastic large cell lymphomas. Pathobiology 65: 83-90
10. French LE and Tschopp J (1996) Constitutive Fas Ligand expression in several non-lymphoid mouse tissues and implications for immune-protection and cell turnover. Behring Inst Mitt 97: 156-160
11. French LE, Hahne M, Vicard I, Radlgruber G, Zanone R, Becker K, Möller C and Tschopp J (1996) Fas and Fas ligand in embryos and adult mice: ligand expression in several immune privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 133: 335-343
12. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH and Runkel L (1995) Involvement of the CD95 receptor and ligand in liver damage. J Exp Med 182: 1223-1230
13. Griffith TS, Brunner TH, Fletcher SM, Green DR and Ferguson TA (1995) Fas ligand induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192
14. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini JC and Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) Ligand: implications for tumour immune escape. Science 274: 1363-1366
15. James-Yarish M, Bradley WG, Emmanuel PJ, Good RA and Day NK (1994) Detection of cell specific cluster determinant expression by reverse transcription polymerase chain reaction. J Immunol Meth 169: 73-82
16. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG and Baekkeskov S (1997) Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med 3: 738-743
17. Kemmner W, Schlag P and Brossmer R (1987) A rapid and simple procedure for dissociation of tumour tissue from the human colon. J Cancer Res Clin Oncol 113: 400-401
18. Möller P, Koretz K, Leihäuser F, Brüderlein S, Henne C, Quentmeier A and Krammer PH (1994) Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int J Cancer 57: 371-377
19. Mulder WMC, Bloemena E, Stukart MJ, Kummer JA, Wagstaff RJ and Scheper RJ (1997) T-cell receptor-zetta and granzyme B exxpression in mononuclear cell infiltrates in normal colonic mucosa and colon carcinoma. Gut 40: 113-119
20. Nagala S and Golstein P (1995) The Fas death factor. Science 267: 1449-1456
21. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno T, Knapp DJ, Green DR and Kratzke RA (1997) Human lung carcinomas express Fas-ligand. Cancer Res 57: 1007-1012
22. O'Connell J, Sullivan GC and Collins JK (1996) The Fas counterattack: Fas-mediated T-cell killing by colon cancer cells expressing Fas-Ligand. J Exp Med 184: 1075-1082
23. Oshimi Y, Oda S, Honda Y, Nagata S and Miyazaki S (1996) Involvement of Fas Ligand and Fas mediated pathway in the cytotoxicity of human natural killer cells. J Immunol 157: 2909-2915
24. Østenstad B, Lea T, Schlichting E and Harboe M (1994) Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45R0 molecule, showing a primed population of lymphocytes in the tumour area. Gut 35: 382-387
25. Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning, a Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY
26. Seino KI, Kayagaki N, Okumura K and Yagita H (1997) Antitumour effect of locally produced CD95 ligand. Nature Med 3: 165-170
27. Shimizu Y, Watanabe A and Whiteside TL (1992) Memory T-lymphocytes are the main population of tumour infiltrating lymphocytes obtained from human primary liver tumours. J Hepatol 16: 197-202
28. Shiraki K, Tsuji N, Shioda T, Isselbacher J and Takahashi H (1997) Expression of Fas-ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94: 6420-6425
29. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells - a mechanism of immune evasion? Nature Med 2: 1361-1366
30. Strasser A and O'Connor L (1998) Fas ligand - caught between scylla and charybdis. Nature Med 4: 21-23
31. Suda T, Takahashi T, Golstein P and Nagata S (1993) Molecular cloning and expression of FasL, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178
32. Walker PR, Saas P and Dietrich PY (1997) Role of FasL in immune escape - the tumour cell strikes back. J Immunol 158: 4521-4524
33. Zeytun A, Hassuneh M, Nagarkatti M and Nagarkatti PS (1997) Fas-Fas ligand-based interactions between tumour cells and tumour-specific cytotoxic T lymphocytes: a lethal two-way street. Blood 90: 1952-1959